Accelerated intermittent theta-burst stimulation for depression: Current evidence and practical considerations
International Journal of Brain Stimulation · 30.06.2026 · 1 (1) · 39-50
DOI: 10.67731/ijbs.1.102 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Brain Stimulation, erschienen am 30.06.2026. Verfasst von Kyu-Man Han. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Depression
Abstract (Originalsprache)
Major depressive disorder (MDD) is a leading contributor to global disability, affecting more than 280 million people worldwide [1].Despite the availability of well-established pharmacotherapy and psychotherapy approaches, the landmark Sequenced Treatment Alternatives to Relieve Depression study showed that approximately one-third of patients fail to achieve remission after sequential antidepressant trials, defining the clinically challenging entity of treatment-resistant depression (TRD) [2].TRD is associated with elevated functional impairment, suicide risk, and economic burden; therefore, there is a considerable need for effective, rapid, and tolerable interventions in this population [3,4].Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (L-DLPFC) has become an established noninvasive option for depression.The original multisite trial by O'Reardon et al. [5] established the efficacy ABSTRACT Accelerated intermittent theta-burst stimulation (iTBS), in which multiple sessions are delivered daily over a condensed treatment course, has rapidly emerged as a potentially transformative approach for depression.This narrative review synthesizes the rationale, current evidence, practical considerations, and the safety of accelerated iTBS for major depressive disorder.We performed a focused literature review for pivotal randomized controlled trials, open-label studies, meta-analyses, and consensus guidelines on standard and accelerated iTBS for depression, with an emphasis on protocols delivering at least two iTBS sessions per day to the left dorsolateral prefrontal cortex.Building on the THREE-D non-inferiority trial, which established daily iTBS as non-inferior to high-frequency repetitive transcranial magnetic stimulation (rTMS), accelerated iTBS protocols leveraged spaced-learning principles to compress treatment into days rather than weeks.The Stanford Neuromodulation Therapy protocol of 50 sessions over 5 days with functional connectivity-guided targeting achieved a 52.5% versus 11.1% Montgomery-Åsberg Depression Rating Scale reduction compared with sham in a double-blind randomized controlled trial and was independently replicated with 1-month remission rates of 50.0%versus 20.8%.Meta-analyses confirmed superior response rates compared with sham and a safety profile comparable to once-daily rTMS, with no evidence of increased seizure risk.Accelerated iTBS is a more efficient delivery schedule and a clinically meaningful evolution of TMS therapy.Although questions remain regarding the optimal personalization, ideal pulse dose, and durability of response, the current evidence supports cautious broader implementation, particularly for patients with treatment-resistant depression requiring rapid relief.
Zitieren
APA
Han, K. (2026). Accelerated intermittent theta-burst stimulation for depression: Current evidence and practical considerations. International Journal of Brain Stimulation, 1(1), 39-50. https://doi.org/10.67731/ijbs.1.102
Vancouver
Han K. Accelerated intermittent theta-burst stimulation for depression: Current evidence and practical considerations. International Journal of Brain Stimulation. 2026;1(1):39-50. doi:10.67731/ijbs.1.102
BibTeX
@article{Han2026,
author = {Han, Kyu-Man},
title = {Accelerated intermittent theta-burst stimulation for depression: Current evidence and practical considerations},
journal = {International Journal of Brain Stimulation},
year = {2026},
volume = {1},
number = {1},
pages = {39--50},
doi = {10.67731/ijbs.1.102}
}
EUVIMED